Evidence map›Paper›PMID 39069710›Full record

ReviewCurrent medicinal chemistry2025

Markers of Vascular Dysfunction in Hypertension.

Vasiliki Tsigkou, Evangelos Oikonomou, Panagiotis Theofilis, Konstantinos Zisimos, Aikaterini Tsatsaragkou, Georgios Marinos, Panteleimon Pantelidis, Ourania Katsarou, Manolis Vavuranakis, Gerasimos Siasos and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Novel Biomarkers in Hypertension.Current medicinal chemistry · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vasiliki Tsigkou3rd Department of Cardiology, 'Sotiria' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Evangelos Oikonomou3rd Department of Cardiology, 'Sotiria' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Panagiotis Theofilis1st Department of Cardiology, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Konstantinos Zisimos3rd Department of Cardiology, 'Sotiria' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Aikaterini Tsatsaragkou3rd Department of Cardiology, 'Sotiria' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Georgios Marinos3rd Department of Cardiology, 'Sotiria' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Panteleimon Pantelidis3rd Department of Cardiology, 'Sotiria' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Ourania Katsarou3rd Department of Cardiology, 'Sotiria' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Manolis Vavuranakis3rd Department of Cardiology, 'Sotiria' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Gerasimos Siasos3rd Department of Cardiology, 'Sotiria' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Dimitris Tousoulis1st Department of Cardiology, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension is a modifiable cardiovascular risk factor and displays a rapidly growing incidence due to aging and the acquisition of an unhealthy lifestyle. Hypertension is linked to the development of target organ damage in several vascular beds such as coronary arteries, peripheral, cerebral, and renal arteries. Besides, along with the presence of other cardiovascular risk factors, it aggravates vascular dysfunction due to the aging process. The mechanisms of vascular dysfunction in hypertension are complex and involve excessive salt intake and water retention, activation of neurohormonal systems, induction of endothelial dysfunction of large arteries and microcirculation, development of arterial stiffness, and complex interactions with cellular pathways of inflammation, oxidative stress, and thrombosis. The extent of vascular dysfunction in patients with hypertension can be assessed by evaluating endothelial function, measuring arterial stiffness, and testing the levels of circulating biomarkers of oxidative stress, pro-inflammatory cytokines, and thrombosis. Assessing these markers in subjects with and without hypertension could aid in identifying those at risk of vascular damage and improving risk prediction for future cardiovascular events. While several lifestyle and pharmacological therapies have shown promise in addressing vascular dysfunction in hypertension, none of these biomarkers have been established as an independent risk factor or treatment target. Therefore, in this article, we review the literature on the evidence that exists regarding the role of vascular dysfunction in the pathophysiology, diagnosis, progression, and treatment of hypertension, highlighting the lack of conclusive evidence in this field.

Indexed as

Endothelium, VascularHypertensionBiomarkersHumansOxidative StressBiomarkersarterial stiffnessendothelial dysfunctionHypertensionpathophysiologyprognosistreatmentvascular dysfunction.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.